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time of aortic valve replacement: Is concomitant mitral valve
repair necessary?
Calvin K. N. Wan, MD,a Rakesh M. Suri, MD,a Zhuo Li, MS,b Thomas A. Orszulak, MD,a Richard C. Daly, MD,a
Hartzell V. Schaff, MD,a and Thoralf M. Sundt, III, MDa
Objective: The optimal management of moderate functional mitral regurgitation at the time of aortic valve
replacement remains undefined.
Methods: We retrospectively identified 686 consecutive patients undergoing aortic valve replacement between
1993 and 2006 with at least moderate (grade 2 or more) functional mitral regurgitation. Patients with structural
valve abnormalities or significant coronary artery disease were excluded, leaving 190 in the study. Analyses for
predictors of residual mitral regurgitation and survival were performed. The impact of mitral regurgitation on sur-
vival was further analyzed among 91 patients case matched for age, gender, and left ventricular ejection fraction to
individuals without mitral regurgitation undergoing isolated aortic valve replacement.
Results: The mean age of the study group was 74  11years, 45% were male, and 78% had New York Heart
Association III or IV Class classification. The mean preoperative ejection fraction was 48%  17%. Operative
mortality was 5% (n¼ 9). Follow-up echocardiographic data were available for 88% of patients at discharge and
57% of patients at midterm. Mitral regurgitation was improved at discharge in 76% of patients and at mid-term
follow-up in 67% of patients. Independent predictors of improved mitral regurgitation were lesser degrees of pre-
operative tricuspid regurgitation or prebypass mitral regurgitation, absence of cerebrovascular disease, and lower
left ventricular ejection fraction. Postoperatively, 89% of patients were New York Heart Association Class I or II
Symptom; No reoperations for mitral regurgitation were performed. Survival was 68% at 5 years and 42% at 10
years. Independent predictors of late mortality were increasing age, diabetes, dialysis-dependent renal failure, and
increased tricuspid regurgitation severity. The survival of 91 patients from this cohort did not differ from case-
matched patients without mitral regurgitation undergoing aortic valve replacement (P ¼ .33).
Conclusion: Moderate functional mitral regurgitation improved in most patients after aortic valve replacement.
Residual mitral regurgitation did not affect survival independently of left ventricular function.
Wan et al Acquired Cardiovascular DiseaseEarn CME credits at
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Supplemental material is available online.
Some degree of functional mitral regurgitation (MR) in the
absence of structural mitral valve disease1 is present in up
to 75% of patients undergoing aortic valve replacement
(AVR).2 Despite the frequency with whichMR is seen, there
remains controversy regarding its management. The major-
ity of prior reports have involved relatively small sample
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organic mitral valve disease or ischemic heart disease. Fur-
thermore, although some reports have shown improvement
in functional MR in up to half of patients undergoing
AVR,2-8 no studies to date have clearly demonstrated
whether improvement in functional MR affects survival.
We therefore sought to determine the 1) impact of AVR
alone on functional MR of at least moderate degree, 2) pre-
dictors of change in MR, and 3) survival of patients with
concomitant moderate functional MR undergoing AVR
compared with a matched cohort without MR.
PATIENTS AND METHODS
Study Population
After obtaining approval from the institutional review board with
a waiver of requirement for individual patient consent, we identified 5855
patients who underwent AVR or aortic root replacement between January
1993 and June 2006 through interrogation of the Society of Thoracic Sur-
geons compliant Mayo Clinic Rochester institutional database for cardio-
vascular surgery. Of these, 686 patients had concomitant MR of at least
moderate degree (Figure 1). In the interest of examining most precisely
the impact of AVR on functional MR secondary to the aortic valvular dis-
ease itself, we excluded those who underwent concomitant coronary artery
bypass grafting; those with significant coronary artery disease, as defined by
greater than 70% stenosis of the left anterior descending, circumflex, or
right coronary artery, or greater than 50% stenosis of the left main coronaryardiovascular Surgery c Volume 137, Number 3 635
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DAbbreviations and Acronyms
AR ¼ aortic regurgitation
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
LV ¼ left ventricular
LVEDD ¼ left ventricular end-diastolic dimension
LVEF ¼ left ventricular ejection fraction
MR ¼ mitral regurgitation
NYHA ¼ New York Heart Association
TR ¼ tricuspid regurgitation
artery; and those with a history of myocardial infarction. We also excluded
those with prior cardiac operation or mitral intervention, hypertrophic car-
diomyopathy, infective endocarditis, connective tissue disease, and congen-
ital or other organic causes of MR, including myxomatous or rheumatic
causes. After excluding those in whom consent for research was not docu-
mented, 190 patients were included in the study cohort.
Definition and Grading of Functional Mitral
Regurgitation
All patients underwent preoperative 2-dimensional echocardiography.
The diagnosis of functional MR was made only after elimination of struc-
tural causes of MR. Although quantitative assessment of the degree of
MR has become part of our standard clinical practice recently, over the
course of the entire study period the degree of MR was determined semi-
quantitatively. In most cases this was determined by examining parameters
such as regurgitant jet area, vena contracta, and flow-convergence (proximal
isovelocity surface area) on color-flow Doppler; jet profile in continuous-
wave Doppler; and flow quantitation with pulse Doppler.9 Preoperative
proximal isovelocity surface area measurements were available in 34% of
the study group. Intraoperative transesophageal echocardiography is routine
in our practice and was performed in all patients in the study group.Surgical Data
All patients had severe aortic stenosis (AS), aortic regurgitation (AR), or
a combination of these pathologies. Aortic valve or aortic root replacement
with or without other associated procedures were performed using cardio-
pulmonary bypass (2.4 L/min1/m2) at normothermia or mild (32C) hypo-
thermia. In the majority of patients, antegrade cold blood cardioplegia was
used for myocardial protection. In 3 patients, hypothermic circulatory arrest
was required for hemiarch replacement of the aorta.
Follow-up
Survival data were obtained through review of patient medical re-
cords and the Social Security database, as well as through postal surveys
administered by the Mayo Survey Research Center. Late follow-up of
functional status and echocardiographic parameters, obtained through pa-
tient chart review, was available in 53% and 57% of survivors at 3.5 
2.8 years and 3.0  2.6 years, respectively. Although this represents
only a fraction of the whole study population, those for whom echocar-
diographic follow-up are available have baseline characteristics similar
to the overall cohort (data not shown). Echocardiographic assessment
was available in 159 patients (88%) at the time of discharge, however.
Survival data were available in 94% of patients (n ¼ 179) at a mean of
3.8  3.6 years. Early mortality was defined as in-hospital or within 30
days of discharge. Late mortality was death occurring beyond this
period.
Survival was further examined by case-matched comparison of patients
with and without MR at the time of AVR. Cases and control patients were
matched with respect to age (5 years), gender (exact match), and left ven-
tricular ejection fraction (LVEF) (10%). Matches were available for 119
patients, of whom survival information was available in 91.
Statistical Analysis
All group data were expressed as mean  standard deviation or fre-
quency and percentage. Continuous variables were compared using analysis
of variance or rank-sum test as appropriate. Categoric variables were com-
pared using chi-square tests. Survival end points were estimated using the
Kaplan–Meier method. Multivariate analysis to identify risk factors forFIGURE 1. Current study cohort of 190 patients with moderate functional MR at the time of aortic valve or root replacement. Flowchart represents appli-
cation of inclusion and exclusion criteria. MR, Mitral regurgitation; MS, mitral stenosis; CAD, coronary artery disease.
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tivariate predictors for residual MR were identified using logistic regression
models. The multivariable model considered univariately significant vari-
ables (P< .05) with model selection using the stepwise method (backward
and forward methods resulted in the same model). All statistical tests were
2-sided with the alpha level set at .05 for statistical significance.
RESULTS
Patient Characteristics
As shown in Table 1, the predominant aortic valve pathol-
ogy was AS in 83% of patients (158), whereas ARwas dom-
inant in 25 patients. Only 7 patients hadmixed AS and AR of
significant degree. Those with AS were almost a decade
older than those with predominant AR (75 vs 67 years,
P< .01). Compared with patients with AS, those with AR
had significantly larger left ventricular end-diastolic dimen-
sion (LVEDD), left ventricular (LV) end-systolic dimension,
LVmass, and LVmass index. Similarly, patients with mixed
AS and AR had a larger LVEDD and LV mass index.
The degree of MR was grade 2 in the majority of patients
(89%), with grade 4 present in only 1 patient. This is likely
a reflection of our collective inclination to intervene on se-
vere MR at the time of AVR. This is also likely responsible
for the underrepresentation of individuals with grade 3 MR.
Operative Characteristics
There were 9 aortic root replacements. Of the 181 AVR
procedures performed, 137 prostheses were biological and
44 prostheses were mechanical, as might be expected given
the age distribution (Table 2). Of these, AVR was performed
as an isolated procedure in 139 patients, with the others un-
dergoing concomitant procedures such as ascending aortic
replacement, tricuspid valve repair or replacement, and the
Maze procedure. A small number of other miscellaneous
procedures were performed: ligation of the left atrial append-
age, limited septal myectomy, right atrial thrombectomy,
and ascending aortic reduction plasty.
Fate of Functional Mitral Regurgitation
At the time of discharge, MR was mild or less in 114
patients (72%) (Table 3). MR was grade 2 in 42 patients
TABLE 1. Baseline characteristics
All patients n ¼ 190 AS n ¼ 158 AR n ¼ 25 Mixed AS/AR n ¼ 7 P value
Age 74  11 75  11 67  10 69  10 <.01
Male 85 (45%) 64 (41%) 17 (68%) 4 (57%) .60
Diabetes 31 (16%) 24 (15%) 5 (20%) 2 (29%) .56
Preoperative renal insufficiency 24 (13%) 19 (12%) 4 (16%) 1 (14%) .85
Dialysis 8 (4%) 7 (4%) 1 (4%) 0 (0%) .85
Hypertension 116 (61%) 94 (59%) 16 (64%) 6 (86%) .36
Cerebrovascular disease 17 (9%) 16 (10%) 1 (4%) 0 (0%) .60
Chronic lung disease 34 (18%) 26 (16%) 4 (16%) 4 (57%) .02
Peripheral vascular disease 26 (14%) 22 (14%) 3 (12%) 1 (14%) .96
NYHA 1 4 (2%) 2 (1%) 1 (4%) 1 (14%) .22
NYHA 2 38 (20%) 30 (19%) 6 (24%) 2 (29%)
NYHA 3 107 (56%) 90 (57%) 13 (52%) 4 (57%)
NYHA 4 41 (22%) 36 (23%) 5 (20%) 0 (0%)
Syncope 14 (8%) 13 (8%) 1 (4%) 0 (0%) .85
CHF 103 (54%) 83 (53%) 18 (72%) 2 (29%) .08
Atrial fibrillation/flutter 46 (24%) 37 (23%) 7 (28%) 2 (29%) .85
LVH on ECG 74 (39%) 61 (39%) 9 (36%) 4 (57%) .89
LVEF 48%  17% 49%  17% 43%  16% 55%  11% .13
Peak gradient 90  27 mm Hg 93  26 mm Hg
Mean gradient 54  18 mm Hg 56  14 mm Hg
MR .55
Grade 2 170 (89%) 142 (90%) 23 (92%) 5 (71%)
Grade 3 19 (10%) 15 (9%) 2 (8%) 2 (29%)
Grade 4 1 (1%) 1 (1%) 0 (0%) 0 (0%)
LVEDD 55  10 53  8 66  10 65  9 <.01
LVESD 44  12 38  11 53  13 44  8 <.01
LV mass 294  107 273  90 371  131 390  145 <.01
LV mass index 157  49 149  42 184  65 199  39 <.01
AS, Aortic stenosis; AR, aortic regurgitation; NYHA, New York Heart Association; CHF, congestive heart failure; ECG, electrocardiogram; MR, mitral regurgitation; LV, left
ventricular; LVH, left ventricular hypertrophy; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end systolic
dimension.
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severity appeared stable at midterm follow-up. Improvement
in MR severity was similar regardless of the functional na-
ture of the aortic valve disease (Table 4). This too appeared
stable at follow-up (mean ¼ 3.0 years). Of particular note,
although 25% and 17% of patients with AS and AR, respec-
tively, had unchanged MR grade, only 1% and 4% of
patients with AS and AR, respectively, had worsened MR
grade at time of discharge. Worsened MR was present at
mid-term in 3 patients with AS (3%) and in zero patients
with AR. There were no reoperations for postoperative
MR identified among the study patients. At a mean fol-
low-up duration of 3.5 years, 25 patients (27%) had New
York Heart Association (NYHA) I classification, 56 patients
(62%) had NYHA II classification, and 10 patients (11%)
had NYHA III classification.
Predictors of Postoperative Improvement in Mitral
Regurgitation
Univariate predictors of improvement inMR at the time of
discharge included younger age, male gender, higher mean
aortic valve gradient, higher body surface area, lower preop-
erative tricuspid regurgitation (TR) grade, larger aortic pros-
thesis, and lower preoperative MR grade under anesthesia.
By multivariate analysis, only TR grade and lower preoper-
ative MR grade under anesthesia remained significant.
Predictors of improvedMR at the time of midterm follow-
up by univariate analysis included absence of cerebrovascu-
lar disease, congestive heart failure at presentation, lower
LVEF, lower preoperative systolic blood pressure, decreased
MR severity at discharge, increased LVEDD, and decreased
septal thickness. In multivariate analysis, however, only ab-
sence of cerebrovascular disease and lower preoperative
LVEF remained (Table 5).
Survival
Early mortality was observed in 9 patients (4.7%). Sur-
vival of the whole cohort was 68% at 5 years and 42% at
10 years (Figure 2, A). When compared with an age- and
gender-matched white population in Minnesota, long-term
survival was significantly lower among the study group
(P<.001). This was true irrespective of the degree of resid-
ual MR postoperatively (Figure 2, B).
Univariate predictors of mortality included increasing
age, severity of diabetes (defined by insulin dependence vs
oral hypoglycemic vs diet controlled), dialysis dependence,
higher NYHA functional class, history of syncope, atrial ar-
rhythmias and absence of sinus rhythm, higher degree of TR,
mitral annular calcification, smaller aortic prosthesis size,
and predischarge MR grade of 1 or higher. By multivariate
analysis, however, only increasing age, severity of diabetes,
dialysis dependence, and greater degree of preoperative TR
were independent predictors for overall mortality (Table 6).
Because of this finding of reduced survival below ex-
pected, we further investigated the impact of MR on survival
using a case-matched comparison with individuals undergo-
ing AVR who did not have preoperative MR. In the interest
of distinguishing between the effects of age and ventricular
function, cases were matched for age, gender, and LVEF
with individuals undergoing surgery during the same time
TABLE 2. Concomitant cardiac procedures
All patients n ¼ 190
Aortic valve replacement 181
Mechanical prosthesis 44
Bioprosthesis 137
Aortic root replacement 9
Aortic root augmentation 14
Tricuspid annuloplasty/replacement 9
Ascending aortic replacement 13
Hemiarch replacement 3
Maze/modified Maze 5
Other 9
TABLE 3. Mitral regurgitation grades at discharge and follow-up
MR grade
Discharge <1 23 (14%)
1 91 (57%)
2 42 (26%)
3 3 (2%)
4 0
Follow-up <1 16 (16%)
1 47 (47%)
2 34 (34%)
3 4 (4%)
4 0
MR, Mitral regurgitation.
TABLE 4. Change in mitral regurgitation severity at discharge and
follow-up
All patients AS AR
Discharge Improved 120 (76%)* 96 (74%)* 18 (78%)*
Unchanged 36 (23%) 32 (25%) 4 (17%)
Worsened 2 (1%) 1 (1%) 1 (4%)
Follow-up Improved 68 (67%)* 60 (69%)* 6 (67%)
Unchanged 30 (30%) 24 (28%) 3 (33%)
Worsened 3 (3%) 3 (3%) 0
AS, Aortic stenosis; AR, aortic regurgitation. *P< .0001 versus preoperative MR.
TABLE 5. Independent predictors for postoperative improvement in
mitral regurgitation at discharge and follow-up
Variable OR 95% CI P value
At discharge
Lower TR severity 2.05 1.11–3.79 .02
Lower preoperative MR under anesthesia 3.07 1.30–7.21 .01
At follow-up
Absence of cerebrovascular disease 6.37 1.49–27.22 .01
Lower LVEF 1.04 1.01–1.07 .01
OR, Odds ratio; CI, confidence interval; TR, tricuspid regurgitation;MR, mitral regur-
gitation; LVEF, left ventricular ejection fraction.
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MR. In 91 such pairs, late survival data were available. The
baseline characteristics of both groups were similar, except
that patients with MR from the current cohort of interest
had a higher incidence of chronic renal failure and peripheral
vascular disease than controls. Kaplan–Meier survival
curves of these 2 groups were not significantly different
(Figure 2, C). By multivariate analysis, chronic renal failure
was an independent predictor of mortality (P< .01).
DISCUSSION
The results of our study demonstrate that moderate (grade
2 to 3) functional MR improves in approximately 75% of
patients undergoing AVR for AS or AR and remains stable
in the remainder. Furthermore, progression of MR in this
population seems to be uncommon, as is reoperation for mi-
tral regurgitation. Furthermore, improvement in the degree
ofMR intraoperatively may predict improvement after aortic
valve surgery. Functional status is improved in the majority
of patients after AVR alone. Unfortunately, long-term sur-
TABLE 6. Independent predictors for overall and late mortality
Variable HR 95% CI P value
Overall mortality
Age 1.08 1.04–1.11 <.001
Severity of diabetes 1.45 1.06–1.99 .020
Dialysis 12.42 3.31–46.66 <.001
Late mortality
Age 1.10 1.06–1.14 <.001
Severity of diabetes 1.70 1.17–2.47 .005
Dialysis 16.40 4.03–66.77 <.001
Increased TR severity 1.51 1.05–2.16 .024
HR, Hazard ratio; CI, confidence interval; TR, tricuspid regurgitation.The Journal of Thoracic and Cvival remains below predicted despite successful AVR;
this was independent of persistent MR. Furthermore, we
were unable to demonstrate an impact of MR itself on sur-
vival in comparison with case-matched control patients
free of MR undergoing AVR alone. This exercise may
have been complicated by our effort to control for ventricu-
lar function as LVEF is an imperfect measure of ventricular
function in the presence of MR. The effect, however, should
have been to bias survival against those with MR, since they
would be expected to have artificially high LVEF biasing the
results against those individuals if at all. Taken together,
these data support a highly selective approach to interven-
tion on the mitral valve at the time of AVR when MR is
mild to moderate in the absence of a structural abnormality
or ischemic disease. In the presence of organic mitral dis-
ease, it is our practice to repair or replace the valve. Theman-
agement of ischemic disease remains in our view an issue of
controversy.
Although MR improved in most, it persisted in what was
still a significant percentage of patients. The independent pre-
dictors of immediate improvement included lesser degree of
TR and improvement in MR with anesthesia. Qualitative
echocardiographic estimates notwithstanding, greater de-
grees of TR may reflect more physiologically substantial
MR. Such may be less likely to improve with AVR alone.
A reduction in MR with anesthesia is easy to appreciate as
a predictor of postoperative improvement in the presence
of aortic valve disease, although we recognize that this
same sign is imperfect in the setting of ischemic causes.
Both of these observations may be useful to the clinician in-
sofar as they suggest a lower threshold for intervention on the
valve may be appropriate in the presence of TR, whereas one
may be reassured if the MR improves in the operating room.ardiovascular Surgery c Volume 137, Number 3 639
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of cerebrovascular disease and lower preoperative LVEF.
The relationship between the former and MR is not obvious,
although the cerebrovascular disease may in fact be a surro-
gate for hypertension and subclinical atherosclerotic disease
in other beds, such as the coronary vasculature. This may in
turn correlate with continued ventricular dysfunction and
persistent hypertension.10 With regard to lower LVEF as
a predictor of MR improvement, it is known that ventricular
function improves after AVR even in the presence of preop-
erative ventricular dilatation.11-14 The dilated left ventricle
with lower preoperative LVEF may therefore undergo the
greatest favorable reverse remodeling, thereby reducing
preoperative functional MR to the greatest degree. Similar
findings have been found in another study.5
Our findings are consistent with those of Absil and col-
leagues,15 who reported improvement in MR severity among
the majority of patients with moderate functional MR and no
difference in survival in a case-matched comparison of pa-
tients with mild versus moderate MR at the time of isolated
AVR.15 Among elderly patients (70 years of age), Barreiro
and associates6 foundmoderateMR to be an independent pre-
dictor of late mortality; however, their study group included
individuals with organic or ischemic mitral valve disease
(48%) of patients with moderate MR undergoing AVR.6
Among those with functional MR, the degree of MR im-
proved in more than 80%. In a smaller study, Brasch and
coauthors4 also found improvement in a substantial percent-
age among patients with AS undergoing AVR alone.
The principle limitation of our study is incomplete echocar-
diographic follow-up. Although the patients who underwent
echocardiography were demographically similar to those
who did not, there is significant potential for sampling bias
in the assessment of recurrent MR at the mid-to-late term.
Symptomatic patients may be less likely to return for follow-
up. Echocardiographic follow-up before discharge was avail-
able in the majority of patients, and selection bias was less
likely. As a retrospective study, it is also subject to the biases
inherent in such a design, including information bias, recall
bias, and treatment selection bias.16Despite theseweaknesses,
this is a relatively large study that providedpower to determine
predictors of survival and improvement in MR over time.17 A
matched comparison of patients undergoing AVR without
MR to a subgroup from our cohort was also possible.
CONCLUSIONS
Improvement in functional MR can be expected in the ma-
jority of patients with significant aortic valve pathology after
AVR. Diminished degrees of MR severity under anesthesia
predicts improvement in MR grade by the time of discharge640 The Journal of Thoracic and Cardiovascular Surfrom hospital. Although moderate functional MR in associa-
tion with aortic valve pathology is associated with lower than
predicted survival for age-matched controls, this effect seems
unrelated to the degree of residualMR, suggesting that surgical
correction of coexistent moderate functionalMR at the time of
AVR is unlikely to affect survival; its impact on symptomatol-
ogy remains unclear. A more complete assessment of long-
term functional status is an important area of further study.
Lacking such information thus far, a highly selective approach
to moderate MR at the time of AVR would be appropriate.
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DTABLE E1. Baseline characteristics of case-matched patients
undergoing lone AVR without MR vs. patients in the current cohort
Control
(MR) n ¼ 91
Case
(MRþ) n ¼ 91 P-value
Male 48 (47%) 48 (47%) 1.00
Age 71.6 71.8 0.55
Body surface area 1.93 1.91 0.52
Preop LVEF 54.8% 53.1% 0.47
Aortic prosthesis size 23.4 mm 23.0 mm 0.15
History of smoking 47 (52%) 47 (52%) 1.00
Diabetes 13 (14%) 14 (15%) 0.83
Chronic renal failure 3 (3%) 10 (11%) 0.04
Dialysis-dependence 1 (1%) 2 (2%) 1.00
Hypertension 46 (51%) 56 (62%) 0.14
Pulmonary hypertension 9 (15%) 9 (24%) 0.28
Cerebrovascular accident 3 (3%) 5 (5%) 0.72
Chronic obstructive pulmonary
disease
7 (12%) 10 (26%) 0.07
Peripheral vascular disease 3 (3%) 11 (12%) 0.03
Cerebrovascular disease 6 (7%) 11 (12%) 0.20
NYHA 1 4 (4%) 4 (4%) 0.99
NYHA 2 24 (26%) 22 (24%)
NYHA 3 46 (51%) 48 (53%)
NYHA 4 17 (19%) 17 (19%)The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 3 640.e1
